Skip to content
DataLookout
Menu

NCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 6 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Notable Eligibility criteria expanded, about 16 wordsv8
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 50 to 100
    • Site details revised
    v7
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  5. Notable Primary and study completion dates: Oct 31, 2023 to Oct 31, 2026v5
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cognitive outcomes
Timeframe: Up to 5 years

Secondary (3)

Quality-of-life
Magnetic resonance imaging (MRI) changes
Role of medications indicated to improve memory and cognitive function

Arms and interventions

Observational (neurocognitive assessment, questionnaires, MRI)

Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.

Procedures: Magnetic Resonance Imaging

Other: Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States